Influence of acute normovolaemic haemodilution on the dose–response relationship, time-course of action and pharmacokinetics of rocuronium bromide

Abstract

ANH resulted in prolongation of rocuronium time-course of action, thus careful monitoring of neuromuscular block is recommended in patients who undergo ANH.

Influence of acute normovolaemic haemodilution on the dose–response relationship and time course of action of cisatracurium besylate

“…13 Furthermore, atracurium's volume of distribution at steady state (Vd ss ) and distribution half-life (t 1/2 a) [87.4 (31) ml kg 21 , 2.1 (0.4) min] 14 15 are different from cisatracurium's Vd ss and t 1/2 a [168 (44) ml kg 21 , 6.4 (0.5) min]. 8 13 Whereas, the previously reported succinylcholine, 4 pancuronium, 4 vecuronium, 5 and rocuronium 7 were either depolarizing 4 or aminosteroid neuromuscular blocking drug, 4 5 7 all with distribution features completely different from cisatracurium.…”

“…3 With ANH the amount of red blood cells and other plasma constituents lost during surgical bleeding are reduced through preoperative dilution of the circulating blood volume. Since the first report by Schuh 4 of a significant increase in the potency of succinylcholine and pancuronium with ANH, several publications demonstrated a similar augmentation of vecuronium, 5 atracurium, 6 and rocuronium 7 potencies. Cisatracurium besylate, a benzylisoquinolinium neuromuscular blocking drug, is a purified preparation of 1 of the 10 stereoisomers of atracurium, which retained atracurium's advantage of Hofmann elimination but not atracurium's elimination via the non-specific plasma esterases hydrolysis pathway.…”

Clinical Predictors of Duration of Action of Cisatracurium and Rocuronium Administered Long-Term

“…On the basis of previous publications, we defined a priori the following variables that might influence the variance in duration of action of cisatracurium and rocuronium: weight, 15,16 age, 17 sex, 18 ASA score, 19 blood loss, 20,21 lowest core body temperature, 22 duration of NBD administration, 23 and history of tobacco smoking. [24][25][26] Variables that correlated significantly (P = .15) with the mean dur 25 were included in our multiple regression analysis model, and an association of variables with the dur 25 of the respective NBD was assumed at a significance level of less than .05.…”

“…Both of these NBDs are often used in anesthesia and intensive care medicine. 4 On the basis of published data, we thought that weight, 15,16 age, 17 sex, 18 American Society of Anesthesiologists (ASA) risk score, 19 blood loss (suggesting instability of cardiac output), 20,21 lowest core body temperature, 22 duration of NBD administration, 23 and tobacco smoking history [24][25][26] might contribute to the variance in the mean duration of action of cisatracurium and rocuronium.…”

Practice and bias in intraoperative pain management: results of a cross-sectional patient study and a survey of anesthesiologists

“…Sufficient intraoperative morphine therapy should aim for effective doses (ED) that suppress pain in at least 95% of patients (ED 95 ) similar to what is common practice for local anesthetics (LA) or muscle relaxants. 19 , 20 To assess how anesthesiologists in our cohort treated pain in general, ED 50 and ED 95 dose–effect estimates were calculated as follows.…”